Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Ifosfamide in Pediatric Solid Tumors

Carli M. · Passone E. · Perilongo G. · Bisogno G.

Author affiliations

Division of Haematology-Oncology, Department of Pediatrics, University Hospital, Padova, Italy

Related Articles for ""

Oncology 2003;65(suppl 2):99–104

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: November 04, 2003
Issue release date: November 2003

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms – rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms’ tumor, bone sarcomas and neuroblastoma. Furthermore, an increase in tumor response rate has been observed when ifosfamide has been used in combination with other drugs. The usual dose of ifosfamide varies from 1.8 to 3 g/m2/day for 2–5 days according to the different regimens. Some controversies still exist on the modality of drug administration and more precisely on the time of infusion, however in pediatric practice, short infusion (e.g. 3 h) is usually preferred because of the reduced neurotoxicity in comparison to lengthier administration (e.g. 24 h). Ifosfamide is currently included in the standard therapy of pediatric bone and soft tissue sarcomas. It is also used in a selected high-risk group of patients with Wilms’ tumor, neuroblastoma and germ cell tumors.

© 2003 S. Karger AG, Basel


References

  1. De Kraker J, Voute PA: Ifosfamide, mesna and vincristine in paediatric oncology. Cancer Treat Rev 1983;10(suppl A):165–166.
  2. Pinkerton CR, Rogers H, James C, Bowman A, Barbor PR, Eden OB, Pritchard J: A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol 1985;15:258–262.
  3. Klein HO, Wickramanayake PD, Christian E, Coerper C: Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557). Cancer 1984;54:1193–1203.
  4. Cerny T, Castiglione M, Brunner K, Kupfer A, Martinelli G, Lind M: Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990;335:175.
  5. Antman KH, Ryan L, Elias A, Sherman D, Grier HE: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126–131.
  6. Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR: Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995;5:785–790.
  7. Bisogno G, De Bernardi B, Cordero di Montezemolo L, Mancini A, Di Tullio MT, Tamaro P, Donfrancesco A, Arrighini A, Zanetti I, Carli M: A randomized comparison of ifosfamide administered as continuous or short infusion in children with soft tissue sarcoma. Med Pediatr Oncol 2001;37:181.
    External Resources
  8. Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, Theobald S, Brunat-Mentigny M, Otten J, Voute PA, Habrand JL, Martelli H, Barrett A, Terrier-Lacombe MJ, Oberlin O: Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT-84. Eur J Cancer 1998;34:1050–1062.
  9. Koscielniak E, Harms D, Henze G, Jurgens H, Gadner H, Herbst M, Klingebiel T, Schmidt BF, Morgan M, Knietig R, Treuner J: Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 1999;17:3706–3719.
  10. Carli M, Bisogno G, Guglielmi M, Cecchetto G, De Bernardi B, Donfrancesco A, Mancini AF, Cordero di Montezemolo L, Indolfi P, Bagnulo S, Zanetti I, Masiero L, Ninfo V, Sotti G: Improved outcome for children with embryonal rhabdomyosarcoma: Results of the Italian Cooperative Study. Med Pediatr Oncol 2000;35:191.
    External Resources
  11. Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, Koscielniak E, Treuner J, Pinkerton CR: High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17:2796–2803.
  12. Jurgens H, Exner U, Kuhl J, Ritter J, Treuner J, Weinel P, Winkler K, Gobel U: High-dose ifosfamide with mesna uroprotection in Ewing’s sarcoma. Cancer Chemother Pharmacol 1989;24:S40–S44.
  13. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Gobel U, Treuner J, Voute PA, Zoubek A, Gadner H, Jurgens H: Localized Ewing tumor of bone: Final results of the cooperative Ewing’s Sarcoma Study CESS-86. J Clin Oncol 2001;19:1818–1829.
  14. Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Imeson J, Lewis I: Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol 1998;16:3628–3633.
  15. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694–701.
  16. Bacci G, Picci P, Ferrari S, Mercuri M, Brach del Prever A, Rosito P, Barbieri E, Tienghi A, Forni C: Neoadjuvant chemotherapy for Ewing’s sarcoma of bone: No benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide and doxorubicin in the maintenance phase – Results of two sequential studies. Cancer 1998;82:1174–1183.
  17. Gobel U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D: Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. Ann Oncol 2000;11:263–271.
  18. Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK: Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990;8:1399–1401.
  19. Bisogno G, Dussini N, Moggia D, Perilongo G, Carli M: Pattern of aminoaciduria in patients with soft tissue sarcoma treated with ifosfamide-containing regimens. Am J Pediatr Hematol Oncol 1993;15:S5–S9.
  20. Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP: High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31–36.
  21. Rossi R, Pleyer J, Schafers P, Kuhn N, Kleta R, Deufel T, Jurgens H: Development of ifosfamide-induced nephrotoxicity: Prospective follow-up in 75 patients. Med Pediatr Oncol 1999;32:177–182.
  22. Skinner R, Sharkey IM, Pearson AD, Craft AW: Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 1993;11:173–190.
  23. Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verweij J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, et al: Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer (EORTC), Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993;31:S180–S184.
  24. Stevens M, Flamant F: Ifosfamide for children with solid tumours. Lancet 1990;335:1398–1400.
  25. Treuner J, Koscielniak E, Keim M: Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother Pharmacol 1989;24:S48–S50.
  26. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS: Intergroup rhabdomyosarcoma study. IV. Results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091–3102.
  27. Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J: A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 1986;18:S25–S28.
  28. Pratt CB, Luo X, Fang L, Marina N, Avery L, Furman WL: Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: A single hospital experience. Med Pediatr Oncol 1996;27:145–148.
  29. Harris MB, Cantor AB, Goorin AM, Shochat SJ, Ayala AG, Ferguson WS, Holbrook T, Link MP: Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A Pediatric Oncology Group study. Med Pediatr Oncol 1995;24:87–92.
  30. Tournade MF, Lemerle J, Brunat-Mentigny M, Bachelot C, Roche H, Taboureau O, Olive D, Lejars O, Boilletot A, Demeocq F: Ifosfamide is an active drug in Wilms’ tumor: A phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol 1988;6:793–796.
  31. Pratt CB, Douglass EC, Kovnar EH, Heideman R, Kun L, Avery L, Kellie SJ: A phase I study of ifosfamide given on alternate days to treat children with brain tumors. Cancer 1993;71:3666–3669.
  32. Heideman RL, Douglass EC, Langston JA, Krischer JP, Burger PC, Kovnar EH, Kun LE, Friedman HS, Kadota R: A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: A Pediatric Oncology Group study. J Neurooncol 1995;25:77–84.
  33. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Wesley R, Magrath I: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191–1198.
  34. Kung FH, Pratt CB, Vega RA, Jaffe N, Strother D, Schwenn M, Nitschke R, Homans AC, Holbrook CT, Golembe B et al: Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993;71:1898–1903.
  35. Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, Krischer JP, Murphy SB, Pratt CB, Toledano S et al: Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: A Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 1995;17:265–269.
  36. Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, Laver JH, Reaman GH, Cairo MS: Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: A Children’s Cancer Group report. Ann Oncol 2002;13:460–469.
  37. Gururangan S, Marina NM, Luo X, Parham DM, Tzen CY, Greenwald CA, Rao BN, Kun LE, Meyer WH: Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing’s tumor with Ewing’s-directed therapy. J Pediatr Hematol Oncol 1998;20:55–61.
  38. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial. J Clin Oncol 2002;20:426–433.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: November 04, 2003
Issue release date: November 2003

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.